Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ventyx Biosciences, Inc. - Common Stock (NQ:VTYX)

8.420 +1.050 (+14.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ventyx Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Which stocks have an unusual volume on Friday?
Volume analysis on 2025-10-24: stocks with an unusual volume in today's session. 
Via Chartmill
Crude Oil Surges 5%; American Airlines Shares Jump After Q3 Results
 
Via Benzinga
Here are the top movers in Thursday's session.
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
Most active stocks in Thursday's session
Discover the most active stocks in Thursday's session. Stay informed about the stocks that are generating the most trading volume! 
Via Chartmill
Ventyx Stock Is Rallying Thursday: What's Driving The Surge?
Ventyx Biosciences Inc (NASDAQ:VTYX) shares are surging Thursday after the company announced positive Phase 2 study results for VTX3232. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Which stocks are moving on Thursday?
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
These stocks are gapping in today's session
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
Dow Gains 50 Points; Tesla Shares Slide After Q3 Earnings
 
Via Benzinga
Topics Stocks
Wondering what's happening in today's pre-market session?
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why LendingClub Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Ventyx Biosciences Stock: Retail Buzz Spikes After Phase 2 Win In Obesity And Heart Risk Study
The Phase 2 trial showed VTX3232 cut key inflammation markers like hsCRP by about 78% and IL-6 to below risk thresholds, reinforcing its anti-inflammatory potential. 
Via Stocktwits
Why Ventyx (VTYX) Shares Soared 86.5% After Hours?
Ventyx shares jumped 86.5% in after-hours trading after positive Phase 2 trial results. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Which stocks are moving after the closing bell on Wednesday?
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Ventyx (VTYX) Q2 Net Loss Drops 16%
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Which stocks are gapping on Thursday?
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for Parkinson's disease. 
Via Benzinga
VTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q2 2024
VTYX stock results show that Ventyx Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Dow Edges Lower; Ventyx Biosciences Shares Plummet
 
Via Benzinga
Topics Stocks
Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
 
Via Benzinga
Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump
 
Via Benzinga
Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further
Ventyx Biosciences stock down over 24% on Monday after Phase 2 trial results for Crohn's disease drug VTX958 did not meet primary endpoint. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.